Dr Gabriela Gomez
Economics of Infectious Diseases
Gabriela has over ten years’ experience of research experience in economic and impact evaluation of new technologies, most of it in infectious diseases such as HIV and TB. She works closely with policy and decision makers globally and in-country (Brazil, Peru, Tanzania, South Africa, Zambia, Zimbabwe, Nigeria, Kenya, India, Bangladesh, and China). Her research focuses on the inclusion of economic methods in infectious disease modelling to inform policy and better practice. She obtained her first degree in Biochemistry followed by a MPH at the University of Montpellier, France. After working in Tunisia and South London on projects looking at disease prevalence and prevention programmes tailored to ethnic minorities, she obtained her PhD at Imperial College on STD prevention and control in sex worker populations in Peru. From 2011 to 2016, she led operational research projects evaluating prevention programs for key populations in sub-Saharan Africa. These programs include HIV prevention for truck drivers and sex workers in Zambia, Zimbabwe and South Africa; cardiovascular disease prevention in slums in Kenya and rural Nigeria; expansion of antiretroviral services (PrEP and immediate treatment) for female sex workers in South Africa, and ante-natal care interventions in rural Nigeria. In 2017, she joined the School and the Social and Mathematical Epidemiology Group. She is a member of the TB-MAC modelling consortium and serves on the steering committee of the Centre for the Mathematical Modelling of Infectious Diseases. She leads research on the inclusion of equity cosiderations in transmission modelling to inform priority setting. She plays an active role in the organization of global conferences (International AIDS Society, International Health Economics Association and UNION (TB) Conferences).
My research interests include equity analysis using transmission models and economic evaluations of the scale-up of new/shortened/re-purposed regimens for first line or MDR treatment of TB, and, more broadly, the use of cost data and transmission models in economic evaluations. I am a member of the TB Modelling and Analysis Consortium (TB MAC) and the Global Health Cost Consortium.